Literature DB >> 3297555

The spectrum of disease in lymphatic filariasis.

F Partono.   

Abstract

Lymphatic filariasis affects predominantly the poorer sector of a community, who can least afford to have the disease. According to an estimate by the World Health Organization in 1984, more than 90 million people are currently infected. It is postulated that the different disease manifestations of filariasis are caused by different host immune responses. An understanding of the clinical spectrum of lymphatic filariasis is essential for the effective treatment and control of the disease, and for correctly correlating clinical status with host immune responses. The disease should be divided into lymphatic filariasis caused by adult worms and occult filariasis due to hyper-responsiveness of the host against microfilariae. The acute stage of filariasis is characterized by episodic adenolymphangitis, followed by obstructive lesions one or more decades later. In brugian filariasis, adenolymphangitis is most commonly observed at the inguinal region, and elephantiasis predominantly involves the leg below the knee. In bancroftian filariasis, the lymphatics of the male genitalia are frequently affected, leading to epididymo-orchitis and hydrocele. Lymphatic filariasis runs an accelerated clinical course in previously unexposed adult migrants. Occult filariasis is not a disease of public health importance. It is characterized by lymphadenopathy, asthmatic bronchitis, hypereosinophilia, and an increase in the production of antibodies, especially immunoglobulin, against microfilarial antigens.

Entities:  

Mesh:

Year:  1987        PMID: 3297555     DOI: 10.1002/9780470513446.ch3

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  13 in total

1.  Chlamydia trachomatis in hydrocele fluid.

Authors:  G Satpathy; S Mohanty; S P Pani; S K Panda
Journal:  Genitourin Med       Date:  1997-12

2.  Differential regulation of in vitro humoral and cellular immune responsiveness in Brugia pahangi-infected jirds.

Authors:  R C Prier; P J Lammie
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

Review 3.  Immunopathogenesis of lymphatic filarial disease.

Authors:  Subash Babu; Thomas B Nutman
Journal:  Semin Immunopathol       Date:  2012-10-03       Impact factor: 9.623

Review 4.  Insights into the pathogenesis of disease in human lymphatic filariasis.

Authors:  Thomas B Nutman
Journal:  Lymphat Res Biol       Date:  2013-09       Impact factor: 2.589

5.  The dynamics of microfilaraemia and its relation with development of disease in periodic Brugia malayi infection in south India.

Authors:  S Sabesan; K Krishnamoorthy; K N Panicker; P Vanamail
Journal:  Epidemiol Infect       Date:  1991-10       Impact factor: 2.451

6.  Preadult stage parasites and multiple timed exposure to infective larvae are involved in development of limb edema in Brugia malayi-infected Indian leaf monkeys (Presbytis entellus).

Authors:  P K Murthy; M A Khan; H B Rajani; V M L Srivastava
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

7.  Clinical and pathological aspects of filarial lymphedema and its management.

Authors:  R K Shenoy
Journal:  Korean J Parasitol       Date:  2008-09       Impact factor: 1.341

8.  Assessment of Blood Collection from the Lateral Saphenous Vein for Microfilaria Counts in Mongolian Gerbils (Meriones unguiculatus) Infected with Brugia pahangi.

Authors:  Leanne C Alworth; Roy D Berghaus; Lisa M Kelly; Prasit Supakorndej; Erica J Burkman; Molly D Savadelis; Tanya L Cooper; Gregory W Salyards; Stephen B Harvey; Andrew R Moorhead
Journal:  Comp Med       Date:  2015-12       Impact factor: 0.982

Review 9.  The role of nuclear factor kappa B (NF-κB) in filarial pathology.

Authors:  Fatima Amponsah Fordjour; Ebenezer Asiedu; Amma Larbi; Alexander Kwarteng
Journal:  J Cell Commun Signal       Date:  2021-02-25       Impact factor: 5.908

Review 10.  Filariasis and lymphoedema.

Authors:  K M Pfarr; A Y Debrah; S Specht; A Hoerauf
Journal:  Parasite Immunol       Date:  2009-11       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.